Portfolio Lab

Haemonetics Corp

  • Stock
  • Ticker HAE
  • ISIN US4050241003
  • NYSE

Health care · Medical technology · USA

$120.16 −0.17%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Haemonetics Corp since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

HAEGlobal equities (VT)

$10,000 grew to $30,945. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −68.6% in 01/2022, measured from the peak in 02/2021. The old peak has not been reached again yet.

1-year return
+60.0%
5-year return p.a.
+16.4%
10-year return p.a.
+12.0%
Volatility p.a.
41.9%
Largest decline
−68.6%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue349331321327339346339358
Gross profit194193192195202198203221
Operating income5971545867-235775
EBITDA881008387954.385103
Net income3758343945-203346
Earnings per share0.741.170.700.810.95-0.410.721.00
Balance sheet
Total assets2,5312,4512,4622,4422,4912,3962,3652,411
Liabilities1,6241,6301,5801,5931,5791,6001,5281,512
Equity907821882849911796837898
Cash321307293296363245223261
Long-term debt1,2209219219209201,2201,1691,114
Cash flow
Operating cash flow4411717111947152128
Capital expenditure-8.5-16-3.8-5.0-6.3-18-7.9-15
Free cash flow3510114106875344113

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2018 at +72.3%, weakest 2021 at −55.3%. 7 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
5 Nov 2026$1.00
6 Aug 2026$0.72
20 May 2026−$0.41
5 Feb 2026$0.95
6 Nov 2025$0.81
7 Aug 2025$0.70
21 May 2025$1.17
6 Feb 2025$0.74
7 Nov 2024$0.66
8 Aug 2024$0.74
20 May 2024$0.40
8 Feb 2024$0.61

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€5.0bn
Market cap in trading currency
$5.47bn
Enterprise value
$6.35bn
P/E
53.2
P/S
3.96
P/B
6.09
EV/Sales
4.59
EV/EBITDA
22.2
Earnings yield
1.9%
FCF yield
5.5%

Results (last four quarters)

Revenue
$1.38bn
Gross profit
$824m
EBITDA
$287m
Net income
$104m
Earnings per share
$2.26
Revenue per share
$30.36
Revenue growth
+9.3%
Earnings growth
+19.7%

Profitability

Gross margin
59.6%
Operating margin
12.8%
Net margin
7.5%
Return on equity
11.9%
Return on assets
4.3%

Balance sheet and cash flow

Cash
$261m
Cash per share
$5.73
Financial debt
$1.14bn
Debt/equity %
127
Current ratio
2.84
Book value per share
$19.73
Operating cash flow
$345m
Free cash flow
$298m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
0%
Ex-dividend date
–

Shares and trading

Shares outstanding
45.5m
Volume
380,832
Avg. volume 3 months
713,394
Relative volume
0.6

Price and technicals

Price
$120.16
1 day
−0.2%
52-week high
$127.42
52-week low
$52.24
Distance to 52-week high
−5.7%
Distance to 52-week low
+130.0%
Distance to 50-day line
+4.3%
Distance to 200-day line
+45.4%
RSI (14)
52
Volatility 1M
33.3%

Performance

1 week
−2.3%
1 month
+3.4%
3 months
+10.8%
6 months
+83.5%
YTD
+49.9%
1 year
+59.8%

Dates

Fiscal year end
28 Mar 2026
Most recent quarter
26 Sep 2026

Frequently asked questions

How has HAE performed since 11/2016?

$10,000 grew to $30,945 by 20 Nov 2026, which is +12.0% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is HAE?

Volatility was 41.9% per year, measured on monthly returns. The largest decline from a peak was −68.6%, with the low in 01/2022.

How does HAE compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, HAE returned +12.0% at 41.9%. The correlation of monthly returns was 0.15; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Haemonetics Corp (HAE): Return and risk | Portfolio Lab